Literature DB >> 29331480

Human papillomavirus (HPV) 18 genetic variants and cervical cancer risk in Taizhou area, China.

Hui-Hui Xu1, Ling-Zhi Zheng2, Ai-Fen Lin3, Shan-Shan Dong3, Ze-Ying Chai4, Wei-Hua Yan5.   

Abstract

Human papillomavirus (HPV) type 18 is predominantly associated with the development of cervical adenocarcinomas, whereas data on HPV18 genetic variability in China are limited. HPV18 genetic variants were formed phylogenetic tree, including lineages A, B, and C. We aimed to evaluate the diversity of HPV18 genetic variants by sequencing the entire E6, E7 and L1 genes. Between 2012 and 2015, a total of 138 (0.8%, 138/17669) women with single HPV18 infection were selected in this study. Finally, we observed 122 HPV18 isolates of the complete E6-E7-L1 sequences, and obtained 36 distinct variation patterns which the accession GenBank numbers as KY457805-KY457840. Except KY457805, KY457813, KY457819, KY457827, KY457829, the rest of HPV18 isolates (81.1%, 31/36) are novel variants. All of HPV18 variants belong to lineage A, while no lineage B, and C was found in our population of Taizhou region, Southeast China. Sublineage A1 was the most common variants (85.2%, 104/122), followed by sublineage A4, A3 and A5, while no sublineage A2 was obtained. Based on the tree topologies, there were three newly identified candidates' sublineages A6-A8. Out of 122 women, 67 (54.9%) had diagnosed by biopsy, including 49 women who diagnosed with cervicitis, 12 with cervical intraepithelial neoplasia (CIN)1, 4 with CIN2/3, and 2 with adenocarcinomas, respectively. Nevertheless, there was no association between HPV18 (sub) lineages and CIN1 or worse (CIN1+) lesions comparing with normal biopsies (P = .469). In conclusion, knowledge of the distribution of geographic/ethnical HPV18 genetic diversity provides critical information for developing diagnostic probes, epidemiologic correlate of cervical cancer risk and design of HPV vaccines for targeted populations.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Cervical lesion; Genetic variants; Gynecological cancer; HPV18

Mesh:

Substances:

Year:  2018        PMID: 29331480     DOI: 10.1016/j.gene.2018.01.037

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  Genetic variations in human papillomavirus and cervical cancer outcomes.

Authors:  Janet S Rader; Shirng-Wern Tsaih; Daniel Fullin; Miriam W Murray; Marissa Iden; Michael T Zimmermann; Michael J Flister
Journal:  Int J Cancer       Date:  2019-01-04       Impact factor: 7.396

2.  Fifteen new nucleotide substitutions in variants of human papillomavirus 18 in Korea : Korean HPV18 variants and clinical manifestation.

Authors:  Namhee Kim; Jeong Su Park; Ji Eun Kim; Jae Hyeon Park; Hyunwoong Park; Eun Youn Roh; Jong Hyun Yoon; Sue Shin
Journal:  Virol J       Date:  2020-05-24       Impact factor: 4.099

3.  Association of HLA-G 3' UTR polymorphism and expression with the progression of cervical lesions in human papillomavirus 18 infections.

Authors:  Hui-Hui Xu; Xia Zhang; Hai-Hong Zheng; Qiu-Yue Han; Ai-Fen Lin; Wei-Hua Yan
Journal:  Infect Agent Cancer       Date:  2018-12-29       Impact factor: 2.965

4.  Genetic diversity and phylogenetic analysis of HPV 16 & 18 variants isolated from cervical specimens of women in Saudi Arabia.

Authors:  Khalid Sait; Rola Turki; Adel Mohammed Abuzenadah; Osama H Jiffiri; Abdulbaset Bohmaidah; Sayed Sartaj Sohrab
Journal:  Saudi J Biol Sci       Date:  2018-05-03       Impact factor: 4.219

5.  Rapid and simultaneous visual typing of high-risk HPV-16/18 with use of integrated lateral flow strip platform.

Authors:  Qi Chen; Li Yao; Qian Wu; Jianguo Xu; Chao Yan; Chuanxiang Guo; Chao Zhang; Tao Xu; Panzhu Qin; Wei Chen
Journal:  Mikrochim Acta       Date:  2022-08-25       Impact factor: 6.408

6.  Self-Collected Specimens Revealed a Higher Vaccine- and Non-Vaccine-Type Human Papillomavirus Prevalences in a Cross-Sectional Study in Akuse.

Authors:  Adolf K Awua; Alberto Severini; Edwin K Wiredu; Edwin A Afari; Vanessa A Zubach; Richard M K Adanu
Journal:  Adv Prev Med       Date:  2020-01-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.